Vanguard Group Inc. Decreases Stake in Enovis Corporation $ENOV

Vanguard Group Inc. reduced its stake in shares of Enovis Corporation (NYSE:ENOV) by 1.3% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 6,438,598 shares of the company’s stock after selling 85,637 shares during the period. Vanguard Group Inc. owned approximately 0.11% of Enovis worth $171,524,000 at the end of the most recent reporting period.

Other institutional investors also recently made changes to their positions in the company. Allspring Global Investments Holdings LLC boosted its position in shares of Enovis by 11.6% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 757,673 shares of the company’s stock worth $20,086,000 after purchasing an additional 78,497 shares in the last quarter. Impax Asset Management Group plc boosted its position in shares of Enovis by 47.5% during the 3rd quarter. Impax Asset Management Group plc now owns 310,630 shares of the company’s stock worth $9,425,000 after purchasing an additional 100,000 shares in the last quarter. Invenomic Capital Management LP boosted its position in shares of Enovis by 22.7% during the 3rd quarter. Invenomic Capital Management LP now owns 712,669 shares of the company’s stock worth $21,622,000 after purchasing an additional 131,705 shares in the last quarter. Public Sector Pension Investment Board boosted its position in shares of Enovis by 14.5% during the 3rd quarter. Public Sector Pension Investment Board now owns 222,939 shares of the company’s stock worth $6,764,000 after purchasing an additional 28,236 shares in the last quarter. Finally, Deroy & Devereaux Private Investment Counsel Inc. purchased a new stake in shares of Enovis during the 4th quarter worth $2,929,000. 98.45% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, insider Oliver Engert bought 1,000 shares of the business’s stock in a transaction that occurred on Friday, February 27th. The stock was purchased at an average price of $25.50 per share, with a total value of $25,500.00. Following the purchase, the insider owned 43,640 shares of the company’s stock, valued at $1,112,820. This trade represents a 2.35% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Over the last three months, insiders have bought 5,000 shares of company stock valued at $121,983. Insiders own 2.90% of the company’s stock.

Key Stories Impacting Enovis

Here are the key news stories impacting Enovis this week:

• Positive Sentiment: Enovis reported first-quarter EPS of $0.89, topping estimates of $0.82, while revenue of $589.15 million also beat expectations. Revenue rose 5.4% year over year, signaling solid demand and execution. Article Title
• Positive Sentiment: The company reaffirmed 2026 free cash flow conversion of greater than 25%, suggesting management still sees healthy cash generation despite Middle East and tariff headwinds. Article Title
• Neutral Sentiment: Enovis also reiterated full-year 2026 guidance, with EPS of $3.52 to $3.73 and revenue of $2.3 billion to $2.4 billion, which was roughly in line with analyst expectations and may reassure investors about the company’s near-term outlook. Article Title
• Neutral Sentiment: Wells Fargo lowered its price target on Enovis to $40 from $42, but kept an overweight rating, indicating continued upside potential despite a slightly more cautious valuation view. Article Title

Enovis Price Performance

Enovis stock opened at $26.52 on Monday. The firm’s 50-day simple moving average is $23.86 and its 200 day simple moving average is $25.80. Enovis Corporation has a 52 week low of $21.00 and a 52 week high of $37.85. The firm has a market capitalization of $1.53 billion, a PE ratio of -1.33 and a beta of 1.41. The company has a quick ratio of 1.05, a current ratio of 2.04 and a debt-to-equity ratio of 0.87.

Enovis (NYSE:ENOV) last announced its earnings results on Thursday, May 7th. The company reported $0.89 earnings per share for the quarter, beating the consensus estimate of $0.82 by $0.07. Enovis had a negative net margin of 49.92% and a positive return on equity of 10.32%. The firm had revenue of $589.15 million during the quarter, compared to the consensus estimate of $572.02 million. During the same quarter in the previous year, the company posted $0.81 EPS. The firm’s revenue for the quarter was up 5.4% on a year-over-year basis. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, equities research analysts predict that Enovis Corporation will post 3.62 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms recently commented on ENOV. Zacks Research upgraded shares of Enovis from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, March 4th. BTIG Research boosted their price objective on shares of Enovis from $41.00 to $43.00 and gave the stock a “buy” rating in a research report on Thursday, February 26th. William Blair began coverage on shares of Enovis in a research report on Friday, April 17th. They issued an “outperform” rating on the stock. Wall Street Zen upgraded shares of Enovis from a “hold” rating to a “buy” rating in a research report on Sunday. Finally, Wells Fargo & Company decreased their price objective on shares of Enovis from $42.00 to $40.00 and set an “overweight” rating on the stock in a research report on Friday. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $45.17.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.